scholarly journals Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

2020 ◽  
Vol 11 ◽  
Author(s):  
Hui-Yao Huang ◽  
Cheng-Cheng Liu ◽  
Yue Yu ◽  
Le Wang ◽  
Da-Wei Wu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Economic Evaluation ◽  
Impact Analysis ◽  
Health Economic Evaluation ◽  
Developed Countries ◽  
Pharmacoeconomic Evaluation ◽  
Evaluation Methodology ◽  
Cochrane Library ◽  
Cost Ratio ◽  
Price Discount

Background and Purpose: The availability of oncology biosimilars is deemed as a fundamental strategy to achieve sustainable health care. However, there is scarce systematic evidence on economic effectiveness of cancer biosimilars. We aimed to synthesize evidence from pharmacoeconomic evaluation of oncology biosimilars globally, provide essential data and methodological reference for involved stakeholders.Materials and Methods: This systematic review was conducted in PubMed, embase, the Cochrane library, CRD, ISPOR and NICE utill December 31, 2019. Information on basic characteristics, evaluation methodology and results were extracted. Quality of included studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards Checklist.Results: For 17 studies identified (13 from Europe and four from United States), the overall quality was generally acceptable. A total of seven biological molecules involved with filgrastim, EPOETIN α, and trastuzumab leading the three. The mostly common evaluation perspective was payer, but the time horizon varied greatly. There were ten studies which adopted cost minimization analysis to evaluate efficiency while seven studies adopted budget impact analysis to address affordability, with cost ratio and cost saving being its corresponding primary endpoint. Although the comparability of included studies was limited and specific results were largely affected by uptake and price discount rates of the oncology biosimilar, the comprehensive results consistently favored its promotion.Conclusion: Globally, the economic evaluation of cancer biosimilars is in its initial phase. However, limited evidence from developed countries consistently supported both cost-effectiveness of efficiency and affordability of oncology biosimilars, while they were largely affected by uptake and price discount rate.

scholarly journals Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Haiyin Wang ◽  
Chunlin Jin ◽  
Liang Fang ◽  
Hui Sun ◽  
Wendi Cheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Stereotactic Body Radiotherapy ◽  
Health Economic Evaluation ◽  
Cochrane Library ◽  
Economic Evaluations ◽  
Advanced Hepatocellular Carcinoma ◽  
Noninvasive Treatment

AbstractStereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for hepatocellular carcinoma. SBRT can achieve effective local control, but it requires a relatively high input of resources; this systematic review was performed to assess the cost effectiveness of SBRT in the treatment of hepatocellular carcinoma to provide a basis for government pricing and medical insurance decision-making. The PubMed, EMBASE, Cochrane Library, CNKI, Wanfang and SinoMed databases were searched to collect economic evaluations of SBRT for the treatment of hepatocellular carcinoma from the date of database inception through December 31, 2018. Two reviewers independently screened the studies, extracted the data and performed a descriptive analysis of the basic characteristics, methods of economic evaluation and main results, as well as the quality and heterogeneity of the reports. A total of 5 studies were included. Among them, the level of heterogeneity was relatively acceptable, with a median score of 90%. Four studies were cost-utility analyses (CUAs), and 1 was a cost-effectiveness analysis (CEA). The incremental cost effectiveness ratio (ICER) for sorafenib compared to SBRT was US $114,795 per quality-adjusted life year gained (cost/QALY) in patients with advanced hepatocellular carcinoma. The ICER for proton beam therapy compared to SBRT was US $6465 in patients with inoperable advanced hepatocellular carcinoma. The ICER for SBRT compared to RFA was US $164,660 for patients with unresectable colorectal cancer (CRC) with liver metastases and US $56,301 for patients with early-stage hepatocellular carcinoma. For patients with inoperable localized hepatocellular carcinoma, compared with RFA–SBRT therapy, the ICERs for SBRT–SBRT and SBRT–RFA were US $558,679 and US $2197,000, respectively; RFA–RFA was dominated. In conclusion, there is limited evidence suggesting that SBRT could be cost-effective for highly specific subpopulations of HCC patients, and further economic evaluations based on randomized controlled trials (RCTs) or cohort studies are needed.

scholarly journals Economic evaluation guidelines in low- and middle-income countries: a systematic review

2021 ◽  
Vol 38 (1) ◽  
Author(s):  
Caroline Daccache ◽  
Rana Rizk ◽  
Jalal Dahham ◽  
Silvia M. A. A. Evers ◽  
Mickael Hiligsmann ◽  
...  
Keyword(s):  
Systematic Review ◽  
Economic Evaluation ◽  
Low Income ◽  
Impact Analysis ◽  
Low Income Countries ◽  
Cochrane Library ◽  
Middle Income ◽  
Middle Income Countries ◽  
Similarities And Differences ◽  
Low And Middle Income

Abstract Objectives To systematically identify the latest versions of official economic evaluation guidelines (EEGs) in low- and middle-income countries (LMICs) and explore similarities and differences in their content. Methods We conducted a systematic search in MEDLINE (Ovid), PubMed, EconLit, Embase (Ovid), the Cochrane Library, and the gray literature. Using a predefined checklist, we extracted the key features of economic evaluation and the general characteristics of EEGs. We conducted a comparative analysis, including a summary of similarities and differences across EEGs. Results Thirteen EEGs were identified, three pertaining to lower-middle-income countries (Bhutan, Egypt, and Indonesia), nine to upper-middle-income countries (Brazil, China, Colombia, Cuba, Malaysia, Mexico, Russian Federation, South Africa, and Thailand), in addition to Mercosur, and none to low-income countries. The majority (n = 12) considered cost–utility analysis and health-related quality-of-life outcome. Half of the EEGs recommended the societal perspective, whereas the other half recommended the healthcare perspective. Equity considerations were required in ten EEGs. Most EEGs (n = 11) required the incremental cost-effectiveness ratio and recommended sensitivity analysis, as well as the presentation of a budget impact analysis (n = 10). Seven of the identified EEGs were mandatory for pharmacoeconomics submission. Methodological gaps, contradictions, and heterogeneity in terminologies used were identified within the guidelines. Conclusion As the importance of health technology assessment is increasing in LMICs, this systematic review could help researchers explore key aspects of existing EEGs in LMICs and explore differences among them. It could also support international organizations in guiding LMICs to develop their own EEGs and improve the methodological framework of existing ones.

Systematic review of health economic evaluation studies of dengue vaccines

Vaccine ◽  
2019 ◽  
Vol 37 (17) ◽  
pp. 2298-2310 ◽  
Author(s):  
Patrícia Coelho de Soárez ◽  
Aline Blumer Silva ◽  
Bruno Azevedo Randi ◽  
Laura Marques Azevedo ◽  
Hillegonda Maria Dutilh Novaes ◽  
...  
Keyword(s):  
Systematic Review ◽  
Health Economic ◽  
Economic Evaluation ◽  
Evaluation Studies ◽  
Health Economic Evaluation

scholarly journals Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e017173 ◽  
Author(s):  
Jinghui Wang ◽  
Xiaohang Wu ◽  
Weiyi Lai ◽  
Erping Long ◽  
Xiayin Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Depressive Symptoms ◽  
Meta Analysis ◽  
Significant Proportion ◽  
Depression Scale ◽  
Developed Countries ◽  
Self Report ◽  
Cochrane Library ◽  
Significant Heterogeneity ◽  
Prevalence Of Depression

ObjectivesDepression and depressive symptoms are common mental disorders that have a considerable effect on patients’ health-related quality of life and satisfaction with medical care, but the prevalence of these conditions varies substantially between published studies. The aim of this study is to conduct a systematic review and meta-analysis to provide a precise estimate of the prevalence of depression or depressive symptoms among outpatients in different clinical specialties.DesignSystematic review and meta-analysis.Data sources and eligibility criteriaThe PubMed and PsycINFO, EMBASE and Cochrane Library databases were searched to identify observational studies that contained information on the prevalence of depression and depressive symptoms in outpatients. All studies included were published before January 2016. Data characteristics were extracted independently by two investigators. The point prevalence of depression or depressive symptoms was measured using validated self-report questionnaires or structured interviews. Assessments were pooled using a random-effects model. Differences in study-level characteristics were estimated by meta-regression analysis. Heterogeneity was assessed using standard χ2tests and the I2statistic. The study protocol has been registered with PROSPERO under number CRD42017054738.ResultsEighty-three cross-sectional studies involving 41 344 individuals were included in this study. The overall pooled prevalence of depression or depressive symptoms was 27.0% (10 943/41 344 individuals; 95% CI 24.0% to 29.0%), with significant heterogeneity between studies (p<0.0001, τ2=0.3742, I2=96.7%). Notably, a significantly higher prevalence of depression and depressive symptoms was observed in outpatients than in the healthy controls (OR 3.16, 95% CI 2.66 to 3.76, I2=72.0%, χ2=25.33). The highest depression/depressive symptom prevalence estimates occurred in studies of outpatients from otolaryngology clinics (53.0%), followed by dermatology clinics (39.0%) and neurology clinics (35.0%). Subgroup analyses showed that the prevalence of depression and depressive symptoms in different specialties varied from 17.0% to 53.0%. The prevalence of depression and depressive symptoms was higher among outpatients in developing countries than in outpatients from developed countries. Moreover, the prevalence of depression and depressive symptoms in outpatients slightly decreased from 1996 to 2010. Regarding screening instruments, the Beck Depression Inventory led to a higher estimate of the prevalence of depression and depressive symptoms (1316/4702, 36.0%, 95% CI 29.0% to 44.0%, I2=94.8%) than the Hospital Anxiety and Depression Scale (1003/2025, 22.0%, 95% CI 12.0% to 35.0%, I2=96.6%).ConclusionOur study provides evidence that a significant proportion of outpatients experience depression or depressive symptoms, highlighting the importance of developing effective management strategies for the early identification and treatment of these conditions among outpatients in clinical practice. The substantial heterogeneity between studies was not fully explained by the variables examined.

scholarly journals A SYSTEMATIC REVIEW OF HEPATITIS VIRUS REVIEW STUDIES: A CASE OF HEALTH ECONOMIC EVALUATION ANALYSIS

2017 ◽  
Vol 9 (5) ◽  
pp. 114
Author(s):  
Phuong Hong Le ◽  
Quang Vinh Tran ◽  
Trung Quang Vo
Keyword(s):  
Systematic Review ◽  
Health Economic ◽  
Economic Evaluation ◽  
Systematic Reviews ◽  
Hepatitis Virus ◽  
Health Economic Evaluation ◽  
Current Evidence ◽  
Inclusion Criteria ◽  
Publication Period

Objective: Systematic reviews of economic analysis are necessary for assessing reports and making a decision. A systematic review of systematic reviews is mean of summarizing the current evidence across specialties of the same or very similar intervention, to provide a synthesis treatment effect. The aim of this study was to explore and to assess the quality of systematic reviews conducted hepatitis economic evaluation.Methods: This study was designed as a systematic review following the AMSTAR guideline through Medline, Cochrane, and Science Direct databases. It was scoped in publication period of 2001 and 2016 in international journals. The quality assessment of the included studies was based on AMSTAR checklist. Two authors did the appreciation independently and all the different results were solved by discussion to give the conclusion.Results: 851 publications found, only 25 studies of those met the inclusion criteria. These studies consisted of 5 studies for vaccination and 20 for non-vaccination. There were only 16% (n=4) based on PRISMA guideline; and twenty-one studies (64%) were not showing about the method of the systematic review or not based on any guideline. Only three articles has published in 2016 with a high standard.Conclusion: According to the results of the appraisal AMSTAR checklist, this review shows clearly the current situation and an urgent need for an increase of quality of hepatitis virus review studies based on health economic evaluation.

scholarly journals A Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis

2020 ◽  
Author(s):  
Ting Zhao ◽  
Hasnat Ahmad ◽  
Barbara de Graaff ◽  
Qing Xia ◽  
Tania Winzenberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Health Economic ◽  
Economic Evaluation ◽  
Health Economic Evaluation ◽  
Evaluation Models

Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type 2 diabetes: a systematic review

2019 ◽  
Vol 78 (5) ◽  
pp. 412-435
Author(s):  
Michaela Olm ◽  
Renée G Stark ◽  
Nathanael Beck ◽  
Christina Röger ◽  
Reiner Leidl
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Economic Evaluation ◽  
Healthcare Costs ◽  
Health Economic Evaluation ◽  
Economic Modeling ◽  
Community Dwelling ◽  
Nutritional Interventions ◽  
Healthcare Needs

Abstract Context In recent decades, obesity and type 2 diabetes mellitus (T2DM) have both become global epidemics associated with substantial healthcare needs and costs. Objective The aim of this review was to critically assess nutritional interventions for their impact on healthcare costs to community-dwelling individuals regarding T2DM or obesity or both, specifically using CHEERS (Consolidated Health Economic Evaluation Reporting Standards) criteria to assess the economic components of the evidence. Data Sources Searches were executed in Embase, EconLit, AgEcon, PubMed, and Web of Science databases. Study Selection Studies were included if they had a nutritional perspective, reported an economic evaluation that included healthcare costs, and focused on obesity or T2DM or both. Studies were excluded if they examined clinical nutritional preparations, dietary supplements, industrially modified dietary components, micronutrient deficiencies, or undernutrition; if they did not report the isolated impact of nutrition in complex or lifestyle interventions; or if they were conducted in animals or attempted to transfer findings from animals to humans. Data Extraction A systematic review was performed according to PRISMA guidelines. Using predefined search terms, 21 studies evaluating food habit interventions or taxation of unhealthy foods and beverages were extracted and evaluated using CHEERS criteria. Results Overall, these studies showed that nutrition interventions and taxation approaches could lead to cost savings and improved health outcomes when compared with current practice. All of the included studies used external sources and economic modeling or risk estimations with population-attributable risks to calculate economic outcomes. Conclusions Most evidence supported taxation approaches. The effect of nutritional interventions has not been adequately assessed. Controlled studies to directly measure economic impacts are warranted.

scholarly journals A Systematic Review of Scope and Quality of Health Economic Evaluation Studies in Vietnam

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e103825 ◽  
Author(s):  
Bach Xuan Tran ◽  
Vuong Minh Nong ◽  
Rachel Marie Maher ◽  
Phuong Khanh Nguyen ◽  
Hoat Ngoc Luu
Keyword(s):  
Systematic Review ◽  
Health Economic ◽  
Economic Evaluation ◽  
Evaluation Studies ◽  
Health Economic Evaluation

Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis

2019 ◽  
pp. bmjspcare-2019-001952 ◽  
Author(s):  
Sepide Rezaei ◽  
Saba Ahmadi ◽  
Jeiran Rahmati ◽  
Hossein Hosseinifard ◽  
Afsaneh Dehnad ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prevalence Rate ◽  
Meta Analysis ◽  
Total Sample ◽  
Developed Countries ◽  
Cochrane Library ◽  
Underdeveloped Countries ◽  
Global Prevalence ◽  
Number Of Patients ◽  
Hiv Aids

IntroductionThe incidence of some fatal diseases, including HIV/AIDS, accompanied by depression has become a significant concern in developed, developing and underdeveloped countries. A great deal of time and money are spent on controlling and reducing the complications of this infection across the world. Accordingly, the main purpose of this study was to clarify the global prevalence rate of depression in patients living with HIV/AIDS via a systematic review and meta-analysis.MethodologyAll articles in English, published between 2000 and 2018, were systematically searched from the original databases of Web of Science, PubMed, Scopus, Cochrane Library, Google Scholar and Embase. As a result, a total of 118 articles were identified.ResultsThe total sample size in these articles was 51143 people, and the number of patients suffering from moderate and severe levels of depression was 14 942. The results of the analysis based on the random-effects (DerSimonian and Laird) model revealed that the prevalence rate of depression in patients with HIV/AIDS was 31% (95% CI 28% to 34%), with a 98% heterogeneity index which was reported significant. Meanwhile, the highest prevalence rate of depression based on continent was in South America at 44% (95% CI 35% to 53%) and the lowest rate was in Europe at 22% (95% CI 17% to 27%).ConclusionIn general, there was a higher prevalence rate of depression in developing and underdeveloped countries than in developed countries, which could be attributed to the advancement of science and the possibilities for early diagnosis of this syndrome.Trial registration numberCRD42019119137.

Sign in / Sign up

Export Citation Format

Share Document